TJPC(SH:600488) 智通财经网·2025-10-31 08:09Core Viewpoint - Tianjin Pharmaceutical Industry Co., Ltd. (津药药业) announced that its subsidiary, Tianjin Yaohe Pharmaceutical Co., Ltd. (津药和平), has received the drug registration certificate for Butorphanol Tartrate Injection from the National Medical Products Administration (NMPA) [1] Company Summary - The main component of Butorphanol Tartrate Injection is Butorphanol Tartrate, classified as a second-class psychoactive drug under the national regulations on narcotic and psychotropic drugs [1] - The drug is indicated for the treatment of various cancer-related pain and postoperative pain [1] - In October 2023, Tianjin Yaohe submitted the application for domestic production drug registration to the NMPA, which was accepted [1] - The drug registration certificate was officially granted in October 2025 [1] - To date, Tianjin Yaohe has invested approximately 22 million yuan in the research and development of Butorphanol Tartrate Injection [1]